The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacokinetic (PK) and pharmacodynamics (PD) properties of SC-PEG e. coli L-asparaginase (EZN-2285) in the treatment of patients with acute lymphoblastic leukemia (ALL): Results from Children's Oncology Group (COG) study AALL07P4.
Anne L. Angiolillo
Research Funding - Sigma-Tau
Reuven J. Schore
Research Funding - Sigma-Tau
Gregory H. Reaman
Research Funding - Sigma-Tau
Naomi Joan Winick
Research Funding - Sigma-Tau
Meenakshi Devidas
Research Funding - Sigma-Tau
Hao W. Zheng
Research Funding - Sigma-Tau
Charlotte Wood
Research Funding - Sigma-Tau
Ashley R. Lane
Research Funding - Sigma-Tau
Elizabeth A. Raetz
Research Funding - Sigma-Tau
William L. Carroll
Research Funding - Sigma-Tau
Stephen Hunger
Research Funding - Sigma-Tau